{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:15:55Z","timestamp":1740028555983,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1124\/jpet.103.052886","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T23:17:37Z","timestamp":1058570257000},"page":"616-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Glycoprotein IIb\/IIIa Receptor Antagonist (2 S)-2-[(2-Naphthyl-sulfonyl)amino]-3-{[2-({4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl}amino)acetyl]amino}propanoic Acid Dihydrochloride (CRL42796), in Combination with Aspirin and\/or Enoxaparin, Prevents Coronary Artery Rethrombosis after Successful Thrombolytic Treatment by Recombinant Tissue Plasminogen Activator"],"prefix":"10.1016","volume":"306","author":[{"given":"Ting-Ting","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardaman","family":"Sherigill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry A.","family":"Giboulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict R.","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.052886_bib1","doi-asserted-by":"crossref","unstructured":"Bennett JS (2001) Novel platelet inhibitors. Annu Rev Med 52: 161\u2013184.","DOI":"10.1146\/annurev.med.52.1.161"},{"key":"10.1124\/jpet.103.052886_bib2","doi-asserted-by":"crossref","unstructured":"Channing-Rodgers RP and Levine J (1990) A critical reappraisal of the bleeding time. Semin Thromb Hemostasis 16: 1\u201320.","DOI":"10.1055\/s-2007-1002658"},{"key":"10.1124\/jpet.103.052886_bib3","doi-asserted-by":"crossref","unstructured":"Coller BS (1985) A new murine monoclonal antibody reports an activation dependent change in the conformation and\/or microenvironment of the platelet GPIIb\/IIIa complex. J Clin Investig 75: 101\u2013108.","DOI":"10.1172\/JCI111931"},{"key":"10.1124\/jpet.103.052886_bib4","doi-asserted-by":"crossref","unstructured":"Ervin AL and Peerschke EIB (2001) Platelet activation by sustained exposure to low-dose plasmin. Blood Coagul Fibrinolysis 12: 415\u2013425.","DOI":"10.1097\/00001721-200109000-00001"},{"key":"10.1124\/jpet.103.052886_bib5","doi-asserted-by":"crossref","unstructured":"Falk E (1985) Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and\/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71: 699\u2013708.","DOI":"10.1161\/01.CIR.71.4.699"},{"key":"10.1124\/jpet.103.052886_bib6","doi-asserted-by":"crossref","unstructured":"Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, and Lucchesi BR (2002) Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb\/IIIa receptor antagonist CRL42796. Br J Pharmacol 136: 927\u2013937.","DOI":"10.1038\/sj.bjp.0704744"},{"key":"10.1124\/jpet.103.052886_bib7","doi-asserted-by":"crossref","unstructured":"Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, and Lucchesi BR (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820\u2013825.","DOI":"10.1161\/hc3301.092790"},{"key":"10.1124\/jpet.103.052886_bib8","doi-asserted-by":"crossref","unstructured":"Hennan JK, Willens DE, Driscoll EM, Hong T-t, Giboulot T, and Lucchesi BR (2003) Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb\/IIIa antagonist CRL42796. J Cardiovas Pharmacol, in press.","DOI":"10.1097\/00005344-200307000-00011"},{"key":"10.1124\/jpet.103.052886_bib9","doi-asserted-by":"crossref","unstructured":"Hennekens CH (1990) Role of aspirin with thrombolytic therapy in acute myocardial infarction. Chest 97: 151S\u2013155S.","DOI":"10.1378\/chest.97.4_Supplement.151S"},{"key":"10.1124\/jpet.103.052886_bib10","doi-asserted-by":"crossref","unstructured":"Ishii-Watabe A, Uchida E, Mizuguchi H, and Hayakawa T (2000) On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP. Biochem Pharmacol 59: 1345\u20131355.","DOI":"10.1016\/S0006-2952(00)00279-3"},{"key":"10.1124\/jpet.103.052886_bib11","doi-asserted-by":"crossref","unstructured":"Koller RL (1991) Prevention of recurrent ischemic stroke. Postgrad Med 90: 81\u201384.","DOI":"10.1080\/00325481.1991.11701141"},{"key":"10.1124\/jpet.103.052886_bib12","doi-asserted-by":"crossref","unstructured":"Kuliopulos A, Covic L, Seely SK, Sheridan PJ, Helin J, and Costello C (1999) Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation and implications for thrombolytic therapy. Biochemistry 38: 4572\u20134585.","DOI":"10.1021\/bi9824792"},{"key":"10.1124\/jpet.103.052886_bib13","doi-asserted-by":"crossref","unstructured":"Lam SC (1992) Isolation and characterization of a cymotryptic fragment of platelet glycoprotein IIb\/IIIa retaining Arg-Gly-Asp binding activity. J Biol Chem 267: 5649\u20135655.","DOI":"10.1016\/S0021-9258(18)42815-3"},{"key":"10.1124\/jpet.103.052886_bib14","doi-asserted-by":"crossref","unstructured":"Loscalzo J, Pashe B, Quimet H, and Fredman JE (1995) Platelets and plasminogen activation. Thromb Haemost 74: 291\u2013293.","DOI":"10.1055\/s-0038-1642692"},{"key":"10.1124\/jpet.103.052886_bib15","doi-asserted-by":"crossref","unstructured":"Makkar RR, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, Shah PK, Jordan RE, and Kaul S (1997) Effects of GP IIb\/IIIa receptor monoclonal antibody (7E3), heparin and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 95: 1015\u20131021.","DOI":"10.1161\/01.CIR.95.4.1015"},{"key":"10.1124\/jpet.103.052886_bib16","unstructured":"Marcus AJ (1994) Cellular interactions of platelets in thrombosis in Thrombosis and Hemorrhage (Loscalzo J and Schafer AI eds) pp 279\u2013291, Boston, Blackwell."},{"key":"10.1124\/jpet.103.052886_bib17","doi-asserted-by":"crossref","unstructured":"Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, and Lucchesi BR (1990) Antiplatelet antibody [7E3 F(ab)2 antibody directed against the platelet GP IIb\/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 21: 393\u2013405.","DOI":"10.1016\/0022-2828(89)90650-0"},{"key":"10.1124\/jpet.103.052886_bib18","unstructured":"Peerschke EI (1985) The platelet fibrinogen receptor. Semin Hematol 22: 241\u2013259."},{"key":"10.1124\/jpet.103.052886_bib19","doi-asserted-by":"crossref","unstructured":"Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shatil SJ, Randolph A, Jakubowski JA, Jennings LK, et al. (1997) Effect of calcium on GPIIb\/IIIa interactions with integrilin: enhanced GPIIb\/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium. Circulation 96: 1488\u20131494.","DOI":"10.1161\/01.CIR.96.5.1488"},{"key":"10.1124\/jpet.103.052886_bib20","unstructured":"Plow EF and Ginsberg MH (1989) Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9: 117\u2013156."},{"key":"10.1124\/jpet.103.052886_bib21","doi-asserted-by":"crossref","unstructured":"Rabhi-Sabile S and Pidard D (1995) Exposure of human platelets to plasmin results in expression of irreversibly active fibrinogen receptors. Thromb Haemostas 73: 693\u2013701.","DOI":"10.1055\/s-0038-1653843"},{"key":"10.1124\/jpet.103.052886_bib22","doi-asserted-by":"crossref","unstructured":"Rebello SS, Huang J, Saito K, and Lucchesi BR (1998) The in vivo efficacy of SM-20302, a GPIIb\/IIIa receptor antagonist correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler Thromb Vasc Biol 18: 954\u2013960.","DOI":"10.1161\/01.ATV.18.6.954"},{"key":"10.1124\/jpet.103.052886_bib23","doi-asserted-by":"crossref","unstructured":"Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, and Lucchesi BR (1999) Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion. Eur J Pharmacol 374: 399\u2013410.","DOI":"10.1016\/S0014-2999(99)00324-6"},{"key":"10.1124\/jpet.103.052886_bib24","doi-asserted-by":"crossref","unstructured":"Romson JL, Haack DW, and Lucchesi BR (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 17: 841\u2013853.","DOI":"10.1016\/0049-3848(80)90249-2"},{"key":"10.1124\/jpet.103.052886_bib25","doi-asserted-by":"crossref","unstructured":"Rote WE, Davis JH, Mousa SA, Reilly TM, and Lucchesi BR (1994) Antithrombotic effects of DMP 728, a platelet GPIIb\/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovas Pharmacol 23: 681\u2013689.","DOI":"10.1097\/00005344-199404000-00025"},{"key":"10.1124\/jpet.103.052886_bib26","doi-asserted-by":"crossref","unstructured":"Smith JB and Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature (Lond) 231: 235\u2013237.","DOI":"10.1038\/newbio231235a0"},{"key":"10.1124\/jpet.103.052886_bib27","doi-asserted-by":"crossref","unstructured":"Spinler SA, Hilleman DE, Cheng JW, Howard PA, Mauro VF, Lopez LM, Munger MA, Gardner SF, and Nappi JM (2001) New recommendations from the 1999 American College of Cardiology\/American Heart Association acute myocardial infarction guidelines. Ann Pharmacother 35: 589\u2013617.","DOI":"10.1345\/1542-6270(2001)035<0589:NRFTAC>2.0.CO;2"},{"key":"10.1124\/jpet.103.052886_bib28","doi-asserted-by":"crossref","unstructured":"Steiner B, Cousot D, Trzeciak A, Gillessen D, and Hadvary P (1989) Ca+2-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb\/IIIa complex. J Biol Chem 267: 13102\u201313108.","DOI":"10.1016\/S0021-9258(18)51601-X"},{"key":"10.1124\/jpet.103.052886_bib29","doi-asserted-by":"crossref","unstructured":"Sudo Y and Lucchesi BR (1996) Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 27: 545\u2013555.","DOI":"10.1097\/00005344-199604000-00014"},{"key":"10.1124\/jpet.103.052886_bib30","doi-asserted-by":"crossref","unstructured":"Topol EJ (2000) Acute myocardial infarction: thrombolysis. Heart 83: 122\u2013126.","DOI":"10.1136\/heart.83.1.122"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524308444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524308444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.052886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:29:04Z","timestamp":1739975344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524308444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S0022356524308444"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.052886","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2003,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein IIb\/IIIa Receptor Antagonist (2 S)-2-[(2-Naphthyl-sulfonyl)amino]-3-{[2-({4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl}amino)acetyl]amino}propanoic Acid Dihydrochloride (CRL42796), in Combination with Aspirin and\/or Enoxaparin, Prevents Coronary Artery Rethrombosis after Successful Thrombolytic Treatment by Recombinant Tissue Plasminogen Activator","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.052886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}